Maximum quantity allowed is 999
Please select the quantity
CAS RN: 184475-71-6 | Product Number: C3647
4-(3-Chloro-4-fluorophenylamino)-7-methoxyquinazolin-6-ol
×
![]()
×
Purity: >98.0%(T)(HPLC)
Synonyms:
- O-Desmorpholinopropyl Gefitinib
- 4-(3-Chloro-4-fluoroanilino)-6-hydroxy-7-methoxyquinazoline
Product Documents:
| Size | Unit Price | Same Day | 2-3 Business Days | Other Lead Time |
Shipping Information
|
|---|---|---|---|---|---|
| 1G |
₩52,700
|
7 | 34 | Contact Us | |
| 5G |
₩177,500
|
9 | 34 | Contact Us |
* Please contact our distributor of SEJIN CI Co., Ltd.
if you would like to purchase TCI products. The above prices do not include freight cost, customs charge and other charges to the destination. SEJIN CI Co., Ltd. (Phone: 02-2655-2480 / email:
sales@sejinci.co.kr)
* The storage conditions are subject to change without notice.
* The storage conditions are subject to change without notice.
| Product Number | C3647 |
Purity / Analysis Method 
|
>98.0%(T)(HPLC) |
| Molecular Formula / Molecular Weight | C__1__5H__1__1ClFN__3O__2 = 319.72 |
| Physical State (20 deg.C) | Solid |
| Storage Temperature
|
Refrigerated (0-10°C) |
| Condition to Avoid | Heat Sensitive |
| CAS RN | 184475-71-6 |
| Reaxys Registry Number | 8928756 |
| PubChem Substance ID | 468591210 |
| MDL Number | MFCD09908046 |
Specifications
| Appearance | White to Light yellow powder to crystal |
| Purity(HPLC) | min. 98.0 area% |
| Purity(Nonaqueous Titration) | min. 98.0 % |
| NMR | confirm to structure |
Properties (reference)
| Melting Point | 293 °C |
GHS
Related Laws:
Transport Information:
| H.S.code* | 2933.59-000 |
Application
A Key Synthetic Intermediate of Gefitinib
This product is a key synthetic intermediate of gefitinib (ZD1839) [G0546] which is a potent and selective inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase.
References
- Studies leading to the identification of ZD1839 (iressa): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer
- Improved synthesis of substituted 6,7-dihydroxy-4-quinazolineamines: tandutinib, erlotinib and gefitinib
- Synthesis and in vitro antitumor activities of novel 4-anilinoquinazoline derivatives
Product Documents (Note: Some products will not have analytical charts available.)
Safety Data Sheet (SDS)
Please select Language.
The requested SDS is not available.
Please Contact Us for more information.
Specifications
C of A & Other Certificates
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
Sample C of A
This is a sample C of A and may not represent a recently manufactured lot of the product.
A sample C of A for this product is not available at this time.
Analytical Charts
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
The requested analytical chart is not available. Sorry for the inconvenience.